at Zacks.com (Jan 22, 2015)
Arena Pharmaceutical (ARNA +1.4%) trades in the green today after earlier disclosing the price for a 60-day supply of Belviq 10-mg tablets at $199.50. This compares with Vivus' (VVUS +1%) Qsymia, which retails for $160 per month at a medium dose and $220 per month for the higher dose. Analysts note the success of Belviq will largely depend on lower co-payments and broader insurance coverage, which could come in the next two years.
How did this change your view of ?
More Bullish More Bearish It Didn't
This impact ()
Thanks for sharing your thoughts.
Submit & View Results
From other sites
at Zacks.com (Jan 16, 2015)
at Zacks.com (Jan 15, 2015)
at Benzinga.com (Jan 14, 2015)
at Benzinga.com (Jan 13, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs